AGL: A Potential Drug Target and Biomarker (G178)

Target Name: AGL

NCBI ID: G178

Content of Review Report on AGL Target / Biomarker

AGL

AGL: A Potential Drug Target and Biomarker

Advanced Glycation Load (AGL) is a protein that is derived from the glucose that is present in the body. It is a well-established fact that high levels of AGL can contribute to the development and progression of a variety of diseases, including diabetes. The aim of this article is to discuss AGL as a potential drug target and biomarker.

AGL as a Drug Target

AGL has been shown to play a crucial role in the development and progression of a number of diseases. For example, high levels of AGL have been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. AGL has also been shown to contribute to the development of diseases of the liver, such as non-alcoholic steatohepatitis (NASH).

In addition to its role in disease development, AGL has also been shown to be a potential drug target. The AGL protein has been shown to interact with a variety of different drugs, including those that are used to treat diabetes and other diseases. For example, some studies have shown that AGL can interact with drugs that are used to treat diabetes by increasing the levels of the drug in the body.

AGL as a Biomarker

In addition to its role as a drug target, AGL has also been shown to be a potential biomarker. A biomarker is a substance that is derived from within the body and can be used as a diagnostic or research tool. AGL has been shown to be a potential biomarker for a variety of different diseases, including diabetes.

One of the main advantages of AGL as a biomarker is its ability to be measured and detected in the body. This makes it an attractive candidate for use as a diagnostic tool. In addition, AGL has been shown to be stable and consistent in the body, which is important for use as a biomarker.

AGL as a Potential Drug Target and Biomarker

In conclusion, AGL is a protein that has been shown to play a crucial role in the development and progression of a variety of diseases. It is also a potential drug target and biomarker. Further research is needed to fully understand the role of AGL in disease and to develop effective treatments.

Protein Name: Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase

Functions: Multifunctional enzyme acting as 1,4-alpha-D-glucan:1,4-alpha-D-glucan 4-alpha-D-glycosyltransferase and amylo-1,6-glucosidase in glycogen degradation

The "AGL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets